Precigen (PGEN) Registration Filing summary

Company overview and business model

• Dedicated discovery and clinical-stage biopharmaceutical company focused on next-generation gene and cell therapies for unmet medical needs in immuno-oncology, autoimmune disorders, and infectious diseases.

• Utilizes proprietary technology platforms (UltraCAR-T, AdenoVerse immunotherapy, ActoBiotics) to develop targeted therapies and precision medicine solutions.

• Recently received FDA approval for PAPZIMEOS™ (zopapogene imadenovec-drba) for recurrent respiratory papillomatosis.

• Pipeline includes multiple clinical-stage assets, with some trials paused as part of strategic prioritization.

Financial performance and metrics

• Completed an underwritten public offering in August 2024, raising $30.9 million in net proceeds.

• Private placement in December 2024 raised approximately $78.5 million in net proceeds from the sale of preferred stock and warrants.

Use of proceeds and capital allocation

• Will not receive any proceeds from the resale of shares by selling stockholders; all proceeds go to selling stockholders.